Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-CFB in Paroxysmal Nocturnal Hemoglobinuria with Persistent Anemia
NCT07187401Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2026
- Primary completion
- Nov 2029
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 3
01
Overview
A Phase 2 trial of ALN-CFB in paroxysmal nocturnal hemoglobinuria (PNH), anemia, sponsored by Regeneron Pharmaceuticals. Started Feb 2026; status: recruiting.
02
Drugs
ALN-CFB
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)anemia
Beyond the preview
Go deeper on NCT07187401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07187401.